🏛️ Verified NIH Record • Updated 2026-08-10
Study of CHS-114 in Participants With Advanced Solid Tumors (NCT05635643)
A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Coherus Oncology, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Who can join: Review the eligibility criteria below.
Location: Stanford Cancer Center — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Stanford Cancer Center — Palo Alto, California
- Emory Winship Cancer Institute — Atlanta, Georgia
- University of Louisville — Louisville, Kentucky
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center — Detroit, Michigan
- Washington University — St Louis, Missouri
- University of Cincinnati — Cincinnati, Ohio
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- START- San Antonio — San Antonio, Texas
- START Mountain — West Valley City, Utah
- University of Washington/Fred Hutchinson Cancer Center — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.